The implications of tamper-resistant formulations for opioid rotation

Postgraduate Medicine

Volumn 124, Issue 5, 2012, Pages 101-109

  Pappagallo, Marco ^a   Sokolowska, Marta ^b  

^a New Medical Home for Chronic Pain   (United States)

^b Center of Excellence for Abuse Liability   (United States)

Author keywords

Chronic pain; Opioids; Pain management; Substance abuse; Tamper resistance

Indexed keywords

MORPHINE; MORPHINE PLUS NALTREXONE; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; NALTREXONE; OPIATE; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG; MORPHINE, NALTREXONE COMBINATION; NARCOTIC ANALGESIC AGENT;

ARTICLE; CHRONIC PAIN; DRUG CAPSULE; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OPIATE ADDICTION; PATIENT SELECTION; PRESCRIPTION; TABLET FORMULATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG FORMULATION; DRUG TOLERANCE;

ANALGESICS, OPIOID; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG TOLERANCE; HUMANS; MORPHINE; NALTREXONE; OPIOID-RELATED DISORDERS; OXYCODONE; OXYMORPHONE; PATIENT SELECTION;

EID: 84873254674     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.09.2588     Document Type: Article

References (64)

1. Centers for Disease Control and Prevention, National Center for Health Statistics. New report finds pain affects millions of Americans [press release]. http://www.cdc.gov/media/pressrel/r061115.htm?s_cid=mediarel_r061115. Released November 15, 2006. Accessed July 19, 2012.
2. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
4. Chou R, Qaseem A, Snow V, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-491.
5. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8): 1331-1346.
6. National Center for Health Statistics. Health, United States, 2007. With Chartbook on Trends in the Health of Americans. Hyattsville, MD: US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2007.
7. Sellers EM, Schoedel KA, Romach MK. Update on formulations to deter tampering. Presented at: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence; June 18-23, 2011; Hollywood, FL.
8. Grilo RM, Bertin P, Scotto di Fazano C, et al. Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine. 2002; 69(5):491-494.
9. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304-315.
10. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000;90(4):933-937.
11. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25(9):2133-2150.
12. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. A retrospective study. Acta Anaesthesiol Scand. 1999;43(9):918-923.
13. Barkin RL, Iasco AM, Barkin SJ. Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. In: Boswell MV, Cole BE, eds. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. New York, NY: Taylor and Francis; 2005:789-804.
14. Lötsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacog-enomics J. 2006;6(3):200-210.
15. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience. 2005;133(1):209-220.
16. Pan YX, Xu J, Mahurter L, Bolan E, Xu M, Pasternak GW. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci U S A. 2001;98(24): 14084-14089.
17. Pan YX, Xu J, Mahurter L, Xu M, Gilbert AK, Pasternak GW. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun. 2003;301(4):1057-1061.
18. Reyes-Gibby CC, Shete S, Rakvåg T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130(1-2):25-30.
19. Viganó A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer. 1998;83(6):1244-1250.
20. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74(2):102-112.
21. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med. 1996;2(11):1248-1250.
22. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007;21(2):5-16.
23. Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37(1):17-40.
24. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624.
25. Narabayashi M, Saijo Y, Takenoshita S, et al; Advisory Committee for Oxycodone Study. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol. 2008;38(4):296-304.
26. Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006; 14(1):56-64.
27. Morita T, Takigawa C, Onishi H, et al; Japan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP) Study Group. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage. 2005;30(1): 96-103.
28. Hale ME, Ahdieh H, Ma T, Rauck R; Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175-184.
29. Korkmazsky M, Ghandehari J, Sanchez A, Lin HM, Pappagallo M. Feasibility study of rapid opioid rotation and titration. Pain Physician. 2011;14(1):71-82.
30. Rappaport BA. New Drug Application Approval Letter. Silver Spring, MD: US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfdadocs/appletter/2011/201655Orig1s000Ltr.pdf. December 9, 2011.
31. Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683-694.
32. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5-13.
33. US Food and Drug Administration; US Department of Health and Human Services. FDA approves new formulation for OxyContin [press release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/ucm207480.htm. Released April 5, 2010. Accessed July 19, 2012.
34. Purdue Pharma LP. FDA Advisory Committee on reformulated OxyContin. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrug-sAdvisoryCommittee/UCM249272.pdf. Accessed July 19, 2012.
35. OxyContin® (oxycodone HCl controlled-release tablets) [package insert]. Stamford, CT: Purdue Pharma L.P.; 2011.
36. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8(1):29.
37. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11-18.
38. Black R, Coplan P, Cassidy T, et al. Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIP-PRO sentinal surveillance network. J Pain. 2012;13(4 suppl):S58.
39. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187-189.
40. Bartholomaeus J, Arkenau-Mari E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9(8):879-891.
41. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers [published online ahead of print June 20, 2012]. Drug Alcohol Depend.
42. Benedek IH, Jobes J, Xiang Q, Fiske WD. Bioequivalence of oxymor-phone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther. 2011;5:455-463.
43. Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11(4):303-311.
44. Johnson FK, Stark JG, Bieberdorf FA, Stauffer J. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther. 2010;32(6): 1149-1164.
45. Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29(12): 777-790.
46. Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D. 2011;11(3):259-275.
47. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med. 2010;122(4):112-128.
48. Webster LR, Brewer R, Wang C, et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage. 2010;40(5):734-746.
49. Jang DH, Rohe JC, Hoffman RS, Nelson LS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med. 2010;55(3):303-304.
50. Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6(4):300-303.
51. www.AboutLawsuits.com. Embeda recall issued due to ongoing manufacturing problems. Saiontz and Kirk, PA. http://www.aboutlaw-suits.com/embeda-recall-manufacturing-problems-16891/. Published March 16, Accessed July 19, 2012.
52. OXECTA® (oxycodone HCl, USP) [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2011.
53. Butler SF, Benoit C, Budman SH, et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J. 2006;3:5.
54. Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med. 2010;11(1):81-91.
55. Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M. Adulterants in illicit drugs: a review of empirical evidence. Drug Test Anal. 2011;3(2):89-96.
56. WHO Model List of Essential Medicines. Vol 17. Geneva, Switzerland: The World Health Organization; 2011.
57. EMBEDA® (morphine sulfate and naltrexone hydrochloride) [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2009.
58. De Lima L. International Association for Hospice and Palliative Care list of essential medicines for palliative care. Ann Oncol. 2007;18(2):395-399.
59. OPANA® ER (oxymorphone hydrochloride) [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2012.
60. Pergolizzi JV Jr, Wieman MS, Gould EM. Effect of age and sex on the pharmacokinetics and metabolism of oxymorphone extended-release tablet. Presented at: American Geriatrics Society Annual Meeting; May 2-5, 2012; Seattle, WA.
61. Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain. J Pain Palliat Care Pharmacother. 2010;24(4):333-348.
62. Cassidy TA, McNaughton EC, Butler SF, Budman SH. Changes in prescription opioid abuse after introduction of an abuse deterrent opioid formulation. Presented at: PAINWeek; September 5 -8, 2012; Las Vegas, NV
63. Webster LR, Bath B, Medve RA, Marmon T, Stoddard GJ. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med. 2012;13(6):790-801.
64. National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. http://nationalpaincentre.mcmaster.ca/opioid/. Accessed May 11, 2010.